257 related articles for article (PubMed ID: 21275338)
1. Molecular staging estimates occult tumor burden in colorectal cancer.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
Adv Clin Chem; 2010; 52():19-39. PubMed ID: 21275338
[TBL] [Abstract][Full Text] [Related]
2. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
[TBL] [Abstract][Full Text] [Related]
3. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
[TBL] [Abstract][Full Text] [Related]
4. Previstage GCC test for staging patients with colorectal cancer.
Mejia A; Waldmana SA
Expert Rev Mol Diagn; 2008 Sep; 8(5):571-8. PubMed ID: 18785805
[TBL] [Abstract][Full Text] [Related]
5. GUCY2C molecular staging personalizes colorectal cancer patient management.
Gong JP; Schulz S; Hyslop T; Waldman SA
Biomark Med; 2012 Jun; 6(3):339-48. PubMed ID: 22731908
[TBL] [Abstract][Full Text] [Related]
6. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
Clin Cancer Res; 2011 May; 17(10):3293-303. PubMed ID: 21307149
[TBL] [Abstract][Full Text] [Related]
7. Guanylyl cyclase C as a biomarker in colorectal cancer.
Hyslop T; Waldman SA
Biomark Med; 2013 Feb; 7(1):159-67. PubMed ID: 23387497
[TBL] [Abstract][Full Text] [Related]
8. Molecular staging of node negative patients with colorectal cancer.
Hyslop T; Waldman SA
J Cancer; 2013; 4(3):193-9. PubMed ID: 23459453
[TBL] [Abstract][Full Text] [Related]
9. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.
Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
J Surg Oncol; 2012 Jul; 106(1):24-30. PubMed ID: 22252429
[TBL] [Abstract][Full Text] [Related]
10. Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study.
Chen G; McIver CM; Texler M; Lloyd JM; Rieger N; Hewett PJ; Sen Wan D; Hardingham JE
Dis Colon Rectum; 2004 May; 47(5):679-86. PubMed ID: 15037935
[TBL] [Abstract][Full Text] [Related]
11. Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.
Carlson MR
Mol Diagn Ther; 2009; 13(1):11-4. PubMed ID: 19351210
[TBL] [Abstract][Full Text] [Related]
12. Molecular staging individualizing cancer management.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
J Surg Oncol; 2012 Apr; 105(5):468-74. PubMed ID: 22441898
[TBL] [Abstract][Full Text] [Related]
13. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
Schulz S; Hyslop T; Haaf J; Bonaccorso C; Nielsen K; Witek ME; Birbe R; Palazzo J; Weinberg D; Waldman SA
Clin Cancer Res; 2006 Aug; 12(15):4545-52. PubMed ID: 16899600
[TBL] [Abstract][Full Text] [Related]
14. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
Cancer; 2012 May; 118(9):2532-40. PubMed ID: 21887684
[TBL] [Abstract][Full Text] [Related]
15. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
Cagir B; Gelmann A; Park J; Fava T; Tankelevitch A; Bittner EW; Weaver EJ; Palazzo JP; Weinberg D; Fry RD; Waldman SA
Ann Intern Med; 1999 Dec; 131(11):805-12. PubMed ID: 10610624
[TBL] [Abstract][Full Text] [Related]
16. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
17. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
Frick GS; Pitari GM; Weinberg DS; Hyslop T; Schulz S; Waldman SA
Expert Rev Mol Diagn; 2005 Sep; 5(5):701-13. PubMed ID: 16149873
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients.
Conzelmann M; Dieterle CP; Linnemann U; Berger MR
Int J Cancer; 2003 Nov; 107(4):617-28. PubMed ID: 14520701
[TBL] [Abstract][Full Text] [Related]
19. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial.
Koyanagi K; Bilchik AJ; Saha S; Turner RR; Wiese D; McCarter M; Shen P; Deacon L; Elashoff D; Hoon DS
Clin Cancer Res; 2008 Nov; 14(22):7391-6. PubMed ID: 19010855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
